中国老年抗中性粒细胞胞浆抗体相关肾小球肾炎治疗指南OA
Guidelines for the Treatment of ANCA-Associated Glomerulonephritis in the Elderly in China
抗中性粒细胞胞浆抗体相关肾小球肾炎(anti-neutrophil cytoplasmic antibody-associated glomerulonephritis,AAGN)在老年患者中临床表现隐匿,易延误诊断,合并症多,治疗相关并发症发生率高,预后差,是导致急性肾损伤和终末期肾病的重要病因.本指南由多学科专家制订,涵盖治疗原则、诱导缓解与维持缓解治疗、复发及难治性疾病处理、肾脏替代治疗,以及合并症与并发症管理等内容,旨在为老年AAGN患者提供个体化诊疗意见,改善临床预后.
Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis(AAGN)often presents with clinically insidious features in elderly patients,leading to delayed diagnosis.It is frequently accompanied by multiple comorbidities,a high incidence of treatment-related complications,and poor prognosis,making it a significant cause of acute kidney injury and end-stage renal disease.This guideline,developed by a multidisci-plinary expert panel,covers treatment principles,induction and maintenance of remission,management of re-lapsing and refractory diseases,renal replacement therapy,as well as the management of comorbidities and complications.It aims to provide an individualized diagnostic and therapeutic consensus for elderly patients with AAGN and to improve clinical outcomes.
中国老年医学学会肾脏病学分会ANCA相关血管炎专家组;中华医学会罕见病分会;中华老年医学分会肾脏病学组;陈丽萌
中国医学科学院北京协和医学院,北京协和医院肾内科,北京 100730
医药卫生
抗中性粒细胞胞浆抗体相关肾小球肾炎老年治疗指南
anti-neutrophil cytoplasmic antibody-associated glomerulonephritiselderlytreatmentguideline
《协和医学杂志》 2026 (2)
334-345,12
National Key Research and Development Program of China(2022YFC2703900,2022YFC2703901)National High Level Hospital Clinical Research Funding(2025-PUMCH-C-023)Beijing Natural Science Foundation(7252112)CAMS Innovation Fund for Medical Sciences(CIFMS 2024-12M-C&T-C-003)Beijing High-Level Innovation and Entrepreneurship Talent Support Program-Healthcare Platform leading talent project(G202511003) 国家重点研发计划(2022YFC2703900,2022YFC2703901)中央高水平医院临床科研专项(2025-PUMCH-C-023)北京市自然科学基金(7252112)中国医学科学院医学与健康科技创新工程项目(CIFMS 2024-I2M-C&T-C-003)北京高层次创新创业人才支持计划"医疗卫生平台"领军人才项目(G202511003)
评论